AHA 2017 Scientific Sessions
End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.
SABCS 2021
Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.
SABCS 2022
Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.
American College of Cardiology 2011
Statins are the most widely prescribed agents in the world. While muscle-related adverse effects associated with statins are well known, accurately quantifying their incidence to guide clinicians with respect to lipid management can be difficult, said Richard H. Karas, MD, PhD, Tufts Medical Center, Boston, at ACC.11, the American College of Cardiology's 60th Annual Scientific Session.
SABCS 2021
Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.
SABCS 2022
The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.
AAAAI 2017
Based on the pathophysiological and clinical characteristics of N-ERD, anti-IL 5 therapy may be effective in this patient subgroup.
PainWeek 2013
Multiple inflammatory markers should simultaneously be tested to best detect unresolved inflammation in pain patients according to results presented at PAINWeek 2013 from a study conducted by pain specialist Forest Tennant, MD, DrPH.
ACR/ARHP Annual Meeting 2013
At the 2013 ACR/ARHP Annual Meeting, study authors presented that patients with active rheumatoid arthritis (RA) despite methotrexate (MTX), certolizumab pegol (CZP) + MTX maintained reduction in signs and symptoms through 5 years.
CHEST 2020
End-stage lung disease may significantly increase the risk for gastroesophageal reflux disease (GERD) in patients undergoing lung transplant without primary esophageal disease.